<DOC>
	<DOCNO>NCT01938846</DOCNO>
	<brief_summary>The primary objective trial determine maximum tolerated dos ( MTD ) BI 860585 alone combination exemestane paclitaxel . To determine MTDs , patient enter sequentially escalate dose cohort . Secondary objective objective response disease control accord RECIST criterion version 1.1</brief_summary>
	<brief_title>BI 860585 Dose Escalation Single Agent Combination With Exemestane With Paclitaxel Patients With Various Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Patients histologically cytologically confirm diagnosis advance , measurable evaluable , nonresectable and/or metastatic solid tumour , show progressive ; Patients receive previous standard care therapy disease progress ; 18 year old ; Life expectancy &gt; = 3 month ; Written inform consent accordance International Conference Harmonisation/Good Clinical Practice ( ICH/GCP ) local legislation ; Eastern Cooperative Oncology Group ( ECOG ) , performance score 02 . Additional inclusion criterion combination arm : Patients must confirm progressive disease within last 6 month , ( case measurable disease , progression confirm accord Response Evaluation Criteria Solid Tumours ( RECIST ) criteria version 1.1 ; Patients carry tumour treatment either exemestane paclitaxel would consider appropriate investigator ; Additional inclusion criterion expansion part : Patients must measurable progressive disease within last 6 month documented/proven accord RECIST criterion version 1.1 . Patients enter expansion cohort must also : Arm A : advanced/metastatic solid tumour suitable biopsy must provide informed consent biopsy biomarker analysis . Arm B : cytologically histologically confirm ER+ ( estrogen receptor positive ) advanced/metastatic solid tumour treatment exemestane would consider appropriate investigator . Arm C : advanced/metastatic solid tumour treatment paclitaxel would consider appropriate investigator . Exclusion criterion : Serious concomitant nononcological disease/illness consider investigator incompatible protocol ; Patients untreated symptomatic brain metastasis ; Second malignancy require active therapy ; Clinical Congestive Heart Failure ( CHF ) Grade IIIIV ; Myocardial infarction within last 6 month prior inclusion , symptomatic coronary artery disease ; Adequate bone marrow , liver renal function ; Patients know HIV/hepatitis/active infectious disease consider investigator incompatible protocol ; Patients unable take oral medication ; Chronic diarrhoea gastrointestinal disorder ; Treatment anticancertherapies : cytotoxic standard chemotherapy , immunotherapy , radiotherapy , biological therapy , molecular target investigational drug , within four week first treatment study medication ( within one week noncytotoxic drug ) ; Recovery previous surgery anticancer medical treatment ; Hypersensitivity combination drug excipients ; Patients history uncontrolled diabetes mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>